Finanzen von Fulcrum Therapeutics Inc (FULC)FULCFulcrum Therapeutics Inc

Evaluating the bottom line, Fulcrum Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -32.38%, provide a clear picture of how effectively FULC converts its operational activities into shareholder value.

In the context of the broader market, FULC competes directly with industry leaders such as EIKN and VOGX. With a market capitalization of $287.95M, it holds a significant position in the sector. When comparing efficiency, FULC's gross margin of N/A stands against EIKN's N/A and VOGX's N/A. Such benchmarking helps identify whether Fulcrum Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Fulcrum has reported consistent net losses, with net income to common shareholders reaching -$26,179,000 in Q2 2026. The gross margin has been 0% for several quarters, indicating no profitability from sales.